-
10:56:25 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

ANIP Stock News

06/22/22 6:50 AM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
ANI Pharmaceuticals, Inc. today announced that the Company received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Clorazepate Dipotassium Tablets. The current annual U.S. market for Clorazepate Dipotassium Tablets is approximately $25.8 million, according to IQVIA/IMS Health, a leading healthcare data and...
RHEA-AI
neutral
06/02/22 4:05 PM
Nasdaq : ANIP
acquisitionlow float
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
ANI Pharmaceuticals, Inc. today announced that it intends to cease operations at its Oakville, Ontario, Canada manufacturing plant by first quarter 2023. The Company will transition the majority of products manufactured or packaged in Oakville to one of its three U.S.- based manufacturing sites. The Company is seeking to find potential buyers for the Oakville...
RHEA-AI
positive
06/01/22 4:15 PM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
ANI Pharmaceuticals, Inc. today announced that the Company received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Fludrocortisone Acetate Tablets USP, 0.1 mg. The current annual U.S. market for Fludrocortisone Acetate Tablets, 0.1 mg is approximately $24.2 million, according to IQVIA/IMS Health, a leading...
RHEA-AI
neutral
05/10/22 6:50 AM
Nasdaq : ANIP
low float
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
ANI Pharmaceuticals, Inc. today announced business highlights and financial results for the three months ended March 31, 2022. Driven by the Cortrophin Gel launch, we are increasing our full-year net revenue guidance and continuing to invest to bring this therapy to patients in need,” said Nikhil Lalwani, President and CEO of ANI. Net revenues were $64.5...
RHEA-AI
neutral
04/19/22 6:50 AM
Nasdaq : ANIP
earningslow float
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
ANI Pharmaceuticals, Inc. today announced that the Company will release its first quarter 2022 financial results on Tuesday, May 10, 2022. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:. About ANI ANI...
RHEA-AI
neutral
03/22/22 4:05 PM
Nasdaq : ANIP
managementlow float
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
Dr. Tannenbaum has over 35 years of management experience in the pharmaceutical industry. With her many accomplishments and proven track record of developing and implementing innovative commercial strategies, and driving growth, Dr. Tannenbaum will be a great asset to the Company, especially as we move forward with our commercialization of Purified...
RHEA-AI
very positive
03/15/22 6:50 AM
Nasdaq : ANIP
low float
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
ANI Pharmaceuticals, Inc. today announced business highlights and financial results for the three and twelve months ended December 31, 2021. Received U.S. Food and Drug Administration approval for Purified Cortrophin™ Gel 80 U/mL, an adrenocorticotropic hormone indicated for the treatment of certain chronic autoimmune disorders, and subsequently...
RHEA-AI
neutral